VYGR - Voyager Corp Market Value to Book Value Ratio
The Voyager Therapeutics (VYGR) price chart, serving as confirmation of the market valuation, underscores the importance of maintaining temperature controls during the transport of viral components. The current metric stands at 0.68. Voyager Therapeutics is scaling its TRACER system by entering into B2B agreements with global behemoths. However, business success relies on vector efficiency and the results of Alzheimer's therapy studies, as well as the stability of partnerships with Pfizer and Novartis.
Voyager Therapeutics Inc (VYGR) - metric breakdowns and financial figures
- market value and analyst target forecast:
- market capitalization statistics:
- book capitalization data:
- debt and solvency information:
Debt to Equity Voyager Therapeutics|VYGR - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Voyager Pharma|VYGR - Company Cumulative Debt|Debt to Book Value Voyager Pharma|VYGR - Company Long-Term Debt|Company Short-Term Debt Voyager Therapeutics|Quick Liquidity Indicator voyagertherapeutics.com
- earnings and valuation multiples indicators:
Comprehensive company analysis:Voyager Therapeutics, VYGR
Defensive assets are selected based on the market's ability to revalue real net assets during periods of expansion. For Voyager Therapeutics (VYGR), which develops innovative capsids for CNS therapies, the current ratio of company value to its book capitalization reflects a premium for future technological breakthroughs, measuring the gap between market sentiment and the book value of equity.
Direct competitors
Biogen Inc. (BIIB) - Market Value to Book Value Ratio|neurocrine.com - Market Value to Book Value|Market Value to Book Value Ratio Regencell Bioscience Holdings Limited|Capitalization to Book Value Ratio AXSM (Axsome)|Market Capitalization to Book Value Ratio ACAD|XENE - Market-to-Book Ratio|Viking Therapeutics - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio supernus.com SUPN|CPRX - Market Value to Book Value Ratio|Market Value to Book Value DNLI (Denali)|Harmony Pharma (HRMY) - Market Value to Book Value Ratio|Market-to-Book Ratio Biohaven Corp (BHVN)|Market Cap to Net Assets Ratio AMLX|Market Value to Book Value Ratio TRVI|Market Value to Book Value Ratio Praxis Precision Medicines, Inc. (PRAX)|AVXL - Market-to-Book Ratio|CeriBell Corp - Market Cap to Net Assets Ratio|Prothena (PRTA) - Market-to-Book Ratio|Alector Therapeutics - Market Capitalization to Book Value Ratio|ANNX - Market Capitalization to Book Value Ratio|OMER: Market Capitalization to Book Value Ratio|Market Value to Equity Ratio Neurogene Inc NGNE|ACIU (AC Immune Corp) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Neumora Corp NMRA|Market Value to Book Value Ratio Scilex Holding Company (SCLX)|TVGN (tevogen.com) - Market Value to Book Value|Alpha Cognition Inc. - Market Cap to Net Assets Ratio|Market Value to Book Value CGTX|IKT: Market Cap to Net Assets Ratio|Cassava Pharma - Market Cap to Book Value Multiple|ASRT: Market Capitalization to Book Value Ratio|Coya Therapeutics - Market Value to Book Value|VTGN (VistaGen Therapeutics, Inc.) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Ovid Rx OVID|Market Value to Book Value Ratio Acumen Pharma (ABOS)|CRVO (CervoMed Corporation) - Market Value to Book Value|Market Capitalization to Book Value Ratio ATHE (Alterity Therapeutics Limited)|Market Capitalization to Book Value Ratio Clene Inc CLNN|PEPG - Market Value to Book Value Ratio|Market Capitalization to Net Assets JUNS|RLMD: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Annovis Bio Corporation (ANVS)|Market Cap to Net Assets Ratio GRCE|Market Capitalization to Book Value Ratio fireflyneuro.com|Market Cap to Net Assets Ratio KLTO (Klotho Neurosciences Inc)|Market Cap to Book Value Multiple NRSN|Market Capitalization to Book Value Ratio RVPH (Reviva Pharmaceuticals Holdings)|Market Capitalization to Book Value MetaVia Inc. (MTVA)|NeurAxis, Inc. - Market Capitalization to Book Value Ratio|Helius Medical (HSDT) - Market Cap to Net Assets Ratio|passagebio.com (PASG) - Market Value to Book Value Ratio|NEUP - Market Capitalization to Book Value|Market Cap to Net Assets Ratio NERV|Market Value to Book Value Ratio ATHA|Market Cap to Net Assets Ratio ADXN (Addex Therapeutics)|ALZN - Market-to-Book Ratio|Market Capitalization to Book Value Ratio CYCN (Cyclerion Therapeutics, Inc.)|Market Value to Equity Ratio Protagenic Therapeutics Inc.|KTTA - Market Value to Book Value Ratio|Market Value to Book Value CRGT (Cortigent, Inc.)|Avenue Therapeutics (ATXI) - Market Value to Book Value Ratio|Capitalization to Book Value Ratio BCLI|CARA (Cara Therapeutics) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Chromocell Therapeutics Corp CHRO|Market Cap to Net Assets Ratio ELYM (Eliem Therapeutics)|Market Capitalization to Book Value Ratio intracellulartherapies.com (ITCI)|Market Value to Book Value Ratio Longboard Pharmaceuticals LBPH|Market Value to Book Value MRNS|NKGN - Market Value to Book Value Ratio|Market-to-Book Ratio NeuroBo Pharmaceuticals Inc|SAGE (Sage Therapeutics, Inc) - Market Cap to Net Assets Ratio|SNPX (Synaptogenix, Inc) - Market Value to Book Value Ratio|Market Value to Book Value Ratio Trevena, Inc.|Market-to-Book Ratio Vigil Neuro VIGL|Market Cap to Net Assets Ratio WENA (Anew Medical, Inc.)|CERE - Market-to-Book Ratio